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Update 2011: Clinical and Genetic Issues
in Familial Dilated Cardiomyopathy
Ray E. Hershberger, MD, Jill D. Siegfried, MS
Miami, Florida
A great deal of progress has recently been made in the discovery and understanding of the genetics of familial
dilated cardiomyopathy (FDC). A consensus has emerged that with a new diagnosis of idiopathic dilated cardio-
myopathy (IDC), the clinical screening of first-degree family members will reveal FDC in at least 20% to 35% of
those family members. Point mutations in 31 autosomal and 2 X-linked genes representing diverse gene ontog-
eny have been implicated in causing FDC but account for only 30% to 35% of genetic causes. Next-generation
sequencing methods have dramatically decreased sequencing costs, making clinical genetic testing feasible for
extensive panels of dilated cardiomyopathy genes. Next-generation sequencing also provides opportunities to
discover additional genetic causes of FDC and IDC. Guidelines for evaluation and testing of FDC and IDC are now
available, and when combined with FDC genetic testing and counseling, will bring FDC/IDC genetics to the fore-
front of cardiovascular genetic medicine. (J Am Coll Cardiol 2011;57:1641–9) © 2011 by the American
College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.01.015w
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DSince our 2005 review of familial dilated cardiomyopathy
(FDC) genetics (1), a great deal of additional progress has
been made. We have noted other valuable dilated cardio-
myopathy (DCM) reviews, consensus documents, and
guidelines since 2005 (2–17). We will review key concepts
of genetic research and provide recent updates in FDC
genetics. We also will review the dramatic innovations in
sequencing technologies that are revolutionizing clinical and
research genetic studies. Much of this information is
broadly applicable to all of cardiovascular genetics.
Background: Genetic Studies,
Phenotype, and Genotype
Phenotype studies. In our previous review (1), we cited 19
CM phenotype studies published between 1981 and 2003,
rincipally focused on estimating the fraction of those
atients with idiopathic dilated cardiomyopathy (IDC) who
ere found to have FDC using family history (FH) or
linical screening of family members. Familial dilated car-
iomyopathy is defined most conservatively as DCM meet-
ng criteria for IDC in at least 2 closely related family
embers (1). Large retrospective studies in the 1980s
stimated that 2% to 10% of individuals with IDC had
DC. In the 1990s, studies involving larger cohorts of patients
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2010, accepted January 31, 2011.ith IDC and prospective cardiovascular screening in their
lose relatives estimated that 20% to 48% of individuals with
DC could be shown to have FDC (18–20). A consensus has
merged that FDC will be found in at least 20% to 35%
f those with IDC with clinical screening of first-degree
amily members, when clinical screening includes elec-
rocardiogram and echocardiography or some other mea-
ure of left ventricle size and function. Notably, a family
istory without clinical screening is much less sensitive to
etect FDC (18).
enetics studies. In 2005, we listed 19 genes shown to
ause nonsyndromic DCM in humans (1). We now list 33
enes, 31 autosomal and 2 X-linked (Table 1) (21–83),
ssociated with DCM covering significant gene ontogeny
Table 2). Notably, the frequencies of DCM mutations in
ny 1 gene are low (1% to 6% to 8%), and a genetic cause
s identified in only 30% to 35% of FDC cases (Table 1). In
ontrast, in hypertrophic cardiomyopathy (HCM), a genetic
ause can be found in 50% to 75% of familial cases; in those
atients for which a mutation is identified, more than 80%
an be found in 1 of 2 genes (myosin heavy chain 7,
yosin-binding protein C) (13). By inference from HCM
and long QT syndrome [LQTS] and arrhythmogenic right
entricular dysplasia [ARVD/C] [13,16]), FDC genetics
re inherently more complex.
The number of DCM genes will continue to increase
ith ongoing discovery efforts. Also, “crossover” DCM
henotypes of desmosomal genes usually associated with
RVD/C present as DCM with low frequency (84);
CM phenotypes have also been observed for genesrincipally observed in HCM or LQTS, as previously
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have recently shown that rare
variant genetics are at play in
some cases of peripartum cardio-
myopathy (85–87).
What Has Not Changed
Over the Past 5 Years?
The core approach to human ge-
netic studies remains the same:
the careful and comprehensive
phenotyping of patients and their
family members and then corre-
lating those phenotypes with ge-
netic information. The challenge
of this approach is to assure one-
self that the genetic variation
identified is causative of the phe-
notype of interest.
Gene mutations. The term “mutation” is most commonly
applied in Mendelian disease to one or a short string of
variants in coding DNA (Table 3). The most common are
missense mutations, but less common types include non-
sense, splice site, and short insertion or deletion mutations
(Table 3). Synonymous variants do not change the amino
acid of the codon, whereas nonsynonymous variants do
change the amino acid of the codon.
Classifying variants as disease-causing mutations. As-
certaining whether any one specific variant is causing the
phenotype of interest requires weighing of several types of
evidence, and achieving a high level of certainty for any one
variant is challenging, especially if that variant is novel
(Table 3) (1,88–90). In most cases, the sum of all of the
evidence is required to decide if the identified variants are
relevant (Table 3). As noted in the following, with next-
generation sequencing (NGS) approaches, unique genetic
variants identified in an individual affected with a specific
phenotype can be many—hundreds to thousands—creating
new challenges.
Phenotypic considerations. The term “Mendelian disease”
has been applied to heritable genetic diseases, usually
familial, with identifiable inheritance patterns (dominant or
recessive, and autosomal, X-linked, or mitochondrial) (1).
Many Mendelian diseases are uncommon to rare, with
population frequencies well below 1%. For Mendelian
diseases demonstrating autosomal dominant inheritance
(which is the case in most families with FDC) (1), the most
powerful evidence that a putative mutation is indeed disease
causing is segregation of the variant of interest with the
disease phenotype in at least 1 large, multigenerational
family with multiple affected individuals who carry the
variant and multiple unaffected individuals who do not carry
the variant (Table 3). Multiple large families available to
assess segregation increases the strength of evidence. Al-
Abbreviations
and Acronyms
ARVD/C  arrhythmogenic
right ventricular dysplasia
DCM  dilated
cardiomyopathy
FDC  familial dilated
cardiomyopathy
FH  family history
HCM  hypertrophic
cardiomyopathy
IDC  idiopathic dilated
cardiomyopathy
LQTS  long QT syndrome
NGS  next-generation
sequencing
WGS  whole-genome
sequencingthough this concept is superficially simple, certain featuresof adult-onset Mendelian disease commonly observed with
FDC complicate this approach.
One feature is incomplete penetrance, which refers to
individuals who carry a mutation but do not manifest any
evidence of the disease phenotype. Thus, in gene discov-
ery studies, the absence of a DCM phenotype in someone
carrying a putative disease-causing variant can never be
considered absolute evidence that the variant is not
relevant: the individual in question may simply be man-
ifesting incomplete penetrance. A key corollary for clini-
cians caring for at-risk family members is that a negative
clinical cardiovascular evaluation at any age does not rule
out the possibility that the family member may develop
later disease. This provides the rationale for the periodic
rescreening of at-risk family members who have normal
evaluations.
A related concept, age-dependent or age-related pen-
etrance, is also observed with FDC, in which a disease-
causing mutation usually manifests a disease phenotype only
in the adult years, most commonly in the fourth to sixth
decades or later.
Another feature that complicates FDC assessment is
variable expressivity, which means that only some aspects of
the DCM phenotype are present. For example, only mild
left ventricular enlargement without systolic dysfunction
or the onset of arrhythmia or conduction system disease
with only borderline DCM may be observed. Also, age of
onset can vary significantly, with variable severity of
disease progression. Thus, within a large family with
FDC, a wide range of clinical findings may be present,
without fully developed DCM. Reliance on endopheno-
types (partial phenotypes or subphenotypes) as an indi-
cation of genetic DCM/FDC also has been problematic,
in part because subtle clinical changes may result from
other more common causes of cardiovascular disease,
making it difficult to decipher genetic from nongenetic
cause.
Although usually nonsyndromic, DCM can be included in
syndromic disease involving various organ systems, most com-
monly skeletal muscle disease (muscular dystrophy) (12).
Genotype considerations. Other criteria to assign causal-
ity (Table 3), in addition to segregation of the variant with
the phenotype, include the phenotype’s relative rarity in
control DNA (commonly 1%). The rationale for this is
that if it were common in the population, it would be
unlikely to cause a rare genetic disease. Nevertheless, how
rare is rare (0.01, 0.005, 0.001, 0.0001)? Some
analyses have suggested that the majority of rare alleles
(0.001 to 0.003) may be injurious (91). The caveat with
control DNA is that it should be representative of the race
and/or ethnicity of the family with DCM because variants
observed to be common (1%) in one population can be
rare in a different population.
Conservation of the amino acid or nucleotide (i.e., lack of
variation in the protein structure or specific nucleotide
sequence [92,93] of lower species) is also used to assess
o
estima
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otide position with greater variation in lower species may
have increased tolerance to variants at that position and is
therefore less likely to be disease causing. Other features are
also relevant (Table 3).
Much of this information, vital for discovery efforts, is also
relevant for FDC clinical genetics. These fundamental princi-
Genes Reported in Association With Nonsyndromic DCM*Table 1 Genes Reported in Association With Nonsyndromic DC
Gene† Protein Functio
LMNA Lamin A/C Structure/stability of inner
membrane; gene expre
MYH6 Alpha-myosin heavy chain Sarcomeric protein; muscl
MYH7 Beta-myosin heavy chain Sarcomeric protein; muscl
MYPN Myopalladin Sarcomeric protein; Z-disc
TNNT2 Cardiac troponin T Sarcomeric protein; muscl
SCN5A Sodium channel Controls sodium ion flux
MYBPC3 Myosin-binding protein C Sarcomeric protein; muscl
RBM20 RNA-binding protein 20 RNA-binding protein of spl
TMPO Thymopoietin Also LAP2, a lamin-associ
LAMA4 Laminin alpha 4 Extracellular matrix protei
VCL Metavinculin Sarcomere structure; inter
LDB3 LIM domain-binding 3; cypher;
Z-band alternatively spliced
PDZ motif-containing protein
Cytoskeletal assembly; clu
membrane proteins
TCAP Titin-cap; telethonin Z-disc protein that associa
sarcomere assembly
PSEN1/2 Presenilin 1/2 Transmembrane proteins;
secretase activity
ACTN2 Alpha-actinin 2 Sarcomere structure; anch
myofibrillar actin
CRYAB Alpha B crystallin Cytoskeletal protein
TPM1 Alpha-tropomyosin Sarcomeric protein; muscl
ABCC9 Sulfonylurea receptor 2A Kir6.2 regulatory subunit;
cardiac potassium ATP
ACTC Cardiac actin Sarcomeric protein; muscl
PDLIM3 PDZ LIM domain protein 3 Cytoskeletal protein
ILK Integrin-linked kinase Intracellular serine-threoni
interacts with integrins
TNNC1 Cardiac troponin C Sarcomeric protein; muscl
TNNI3 Cardiac troponin I Sarcomeric protein, muscl
also seen as recessive
PLN Phospholamban Sarcoplasmic reticulum ca
inhibits sarco/endoplas
calcium-ATPase pump
DES Desmin DAGC; transduces contrac
SGCD Delta-sarcoglycan DAGC; transduces contrac
CSRP3 Cysteine- and glycine-rich protein 3;
muscle LIM protein
Sarcomere stretch sensor/
TTN Titin Sarcomere structure/exte
for other proteins
EYA4 Eyes absent 4 Transcriptional coactivator
ANKRD1 Ankyrin repeat domain-containing
protein 1
Cardiac ankyrin repeat pro
to myopalladin/titin co
DMD‡ Dystrophin DAGC; transduces contrac
TAZ/G4.5‡ Tafazzin Unknown
*See reference 12 for dilated cardiomyopathy (DCM) associated with syndromic disease and refere
rdered by estimates of the fraction of DCM probands carrying mutations from primary and secon
DAGC  dystrophin-associated glycoprotein complex; N/A  not available (inadequate data forples of human genetics investigations have not changed;however, with NGS, the quantity of data to which they are
applied has changed dramatically.
Genetic counseling. Text limitations do not permit a
reiteration of the components and importance of skilled
genetic counseling, especially for difficult, confusing, or
syndromic cases, supported by geneticist consultations as
needed (1). Unlike most cardiologists, genetic counselors are
OMIM
Estimated Fraction
of DCM† Ref. #
ar 150330 0.06 21–33
raction 160710 0.043 34,35
raction 160760 0.042 36–39
608517 0.035 40
raction 191045 0.029 36,38,39,41–44
600163 0.026 39,45,46
raction 600958 0.02 35,37
me 0.019
uclear protein 188380 0.011 47
600133 0.011 48
d discs 193065 0.01 38,49
of 605906 0.01 39,50
th titin; 604488 0.01 39,51
a 104311/600759 0.01 52
102573 0.009 53
123590 0.007 54
raction 191010 0.006 35,55,56
ly rectifying
el
601439 0.006 57
raction 102540 0.005 58–63
605889 0.005 64
ase; 602366 0.005 48
raction 191040 0.004 35,43
raction; 191044 0.004 35,65,66
regulator;
ticulum
172405 0.004 38,67–70
ces 125660 0.003 61,71,72
ces 601411 0.003 72–74
s 600824 0.003 39,75
scaffold 188840 N/A 76,77
603550 N/A 78
ocalized 609599 N/A 79
ce 300377 N/A 80,81
300394 N/A 82,83
for genes not listed here that routinely cause combined skeletal and cardiac myopathies. †Genes
ports; all are autosomal except as indicated. ‡X-linked genes.
te); OMIM  Online Mendelian Inheritance in Man.M*
n
nucle
ssion
e cont
e cont
e cont
e cont
iceoso
ated n
n
calate
stering
tes wi
gamm
or for
e cont
inward
chann
e cont
ne kin
e cont
e cont
lcium
mic re
tile for
tile for
Z-disc
nsible
tein; l
mplex
tile for
nce 15
dary retrained to deal with the family as a unit of inquiry rather
M
t
s
s
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Sarcomere Z-Disc Cytoskeleton Mitochondrial
RNA
Binding
Ion
Channel
Gamma Secretase
Activity
Sarcoplasmic
Reticulum
Transcription
Factor
Nuclear
Envelope
ACTC TCAP DMD TAZ/G4.5 RBM20 ABCC PSEN1 PLN EYA4 LMNA
MYH7 CSRP3 DES SCN5A PSEN2 TMPO
MYH6 ACTN2 LDB3
MYBPC3 MYPN SGCD
TNNT2 ANKRD1 PDLIM3
TNNC1 VCL
TNNI3 RYAB
TPM1 ILKTTN LAMA4Considerations for Molecular Genetic TestingTable 3 Considerations for Molecular Genetic Testing
A. Types of molecular genetic variants* Comment
Affects exonic (coding) sequences
Missense Single-base variant that changes amino acid
Nonsense Single-base variant that changes amino acid to stop codon
Insertion/deletion (indel) Usually 1 nucleotide(s) inserted or deleted; unless indel is in a multiple of 3,
a frameshift occurs that garbles usual amino acid sequence, usually
resulting in eventual stop codon
Affects intronic or splice site sequences
Splice site Affects exon splicing; 1 exons may be skipped
Intronic Intronic sequencing is noncoding; although intronic variation is more common
than coding sequence, it is infrequently associated with disease
B. Testing categories of sequence variations relevant to phenotype of interest (90)
Sequence variation has been previously reported and is recognized cause of disorder
Sequence variation has been previously unreported and is of type expected to cause disorder
Sequence variation has been previously unreported and is of type that may or may not be causative of disorder
(also commonly referred to as variant of unknown significance)
Sequence variation has been previously unreported and is probably not causative of disease
Sequence variation has been previously reported and is recognized neutral variant
Sequence variation is not known or expected to be causative of disease but is found to be associated with clinical presentation
C. Criteria used to assess relevance of genetic variant for phenotype of interest
Property Comment
Prior molecular genetic diagnostic classification, if available May be definitive for variants previously established as disease causing
Type of variant (see section A of this table) Synonymous variant only in unusual circumstances is considered relevant for
disease (e.g., variant that opens cryptic splice acceptor site)
Weight of evidence, in the gene in question, that rare nonsynonymous variants
cause DCM
†See comment below
Disruption of a functional protein in the tissue of interest that could lead to plausible
pathophysiology
Examples of established genes include those encoding proteins of contractile
apparatus (see Table 1). This is especially relevant for a novel gene under
consideration in a discovery study. For discovery studies, evidence of
cardiac expression or the presence of the protein product in cardiac tissue
may aid in assessing relevance
Rarity in population Many Mendelian variants may be “private” or unique to proband or family
Variant segregates with DCM phenotype, ideally in 1 large families; lacking large
families, variant segregates with DCM in multiple smaller families or is observed
in multiple patients with sporadic DCM
In genetic DCM (and other multilocus Mendelian diseases), many variants are
“private” so that multiple probands or families with any 1 specific variant
are uncommon
Functional data derived from variant: cellular or animal models that recapitulate the
disease phenotype
All model systems have inherent limitations and seldom provide definitive
studies; however, such functional data increase certainty that the variant
under study is relevant for the phenotype of interest
*These variants do not account for copy number variants (CNVs; also termed structural variants), which are insertions, deletions, duplications, or inversions of larger portions of DNA. CNVs range widely in
size, from very small (100 nucleotides) to very large (manymegabases), with all sizes in between. Theymay affect both coding and noncoding DNA. Structural variants are not detected by usual sequencing
approaches. Systematic evaluation of structural variants has not been undertaken in dilated cardiomyopathy (DCM), and hence, their relevance for DCM has not been established. †Some genes (e.g., LMNA,
YH7, TNNT2; see Table 1) have abundant evidence that point mutations can cause DCM. Nevertheless, because of the marked allelic heterogeneity in DCM genes, it is uncommon for any 1 specific variant
o be found in multiple unrelated probands, even in these genes. Whether any of these novel nonsynonymous rare variants can be considered disease causing by usual molecular genetic diagnostic
tandards is an open question. Further, because most of the DCM genes (Table 1) have had only a few reported pathologic variants, newly identified rare variants in such genes with fewer prior DCM
equencing data available are commonly reported as variants of unknown significance (section B of this table).
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medicine. Genetic counselors are also trained to emphasize
disease prevention in contrast to the focus on disease
treatment taken by most cardiovascular specialists. Both of
these qualities are particularly relevant for facilitating ge-
netic risk assessment. The availability of genetic counselors
with cardiovascular training or experience can provide the
support needed to initiate the practice of cardiovascular
genetic medicine. Several articles deal with these important
points (1,12,15,16,94–96).
What Has Changed Over the Past 5 Years?
Sequencing methods. The most significant change is the
ramatic improvement in efficiency and speed of gene sequenc-
ng methods. Next-generation sequencing is the term used to
escribe several diverse methods that improve sequencing
hroughput by several magnitudes, resulting in markedly
reduced sequencing costs per nucleotide. This has led
recently to sequencing the human exome routinely for
research applications (97–99). The exome is defined as the
protein-coding portion (exons) of the 18,000 to 19,000
genes, estimated at 1% to 2% of the human genome.
Next-generation sequencing is also used to sequence the
entire human genome (coding and noncoding regions of
DNA), referred to as whole-genome sequencing (WGS)
(100). Because Mendelian disease typically affects the
protein-coding portions of the genome, exome sequencing
is particularly relevant for rare-variant Mendelian disease.
As of 2010, typical costs of exome sequencing for research
purposes are approximately $2,000 per DNA sample. New
instruments and new methods for multiplexing DNA on
NGS instruments are being developed that will improve
throughput and decrease cost, making $1,000, or even
$500, exome sequences likely in the near future. Whole-
genome sequencing charges on the open market now range
from $10,000 to $20,000; these costs are also expected to
decrease dramatically (10- to 20-fold) in the next few years,
which will bring even WGS into the realm of clinical
genetic testing, as well as within the domain of the National
Institutes of Health research budgets of many cardiovascular
genetics studies. Next-generation sequencing, whether for
exome sequencing or WGS, is dramatically transforming
the experimental possibilities—study designs unthinkable
even 1 to 2 years ago can now be proposed and completed
(97–99).
Along with this rapidly expanding universe of opportu-
nity from NGS will come monstrous quantities of human
DNA sequence data, challenging the hardware and software
of informatics platforms and necessitating novel approaches
to data assembly, storage, and analysis. Computational
budgets for even modest exome projects (terabytes of data)
now cost tens of thousands of dollars; larger projects
containing hundreds to thousands of terabytes of data will
require more robust outlays. These realities will require new
“pipelines” to be developed to efficiently analyze thesemassive datasets and reduce the cost of storage. This will
also require new control DNA datasets to be generated,
some of which are now underway (101).
Impact of NGS on clinical molecular genetic testing.
Next-generation sequencing is directly related to the emer-
gence of clinical genetic testing for FDC. As recently as 2 to
3 years ago, clinical genetic testing costing thousands of
dollars was available only for a few HCM genes. Now
panels of dozens of genes at reduced cost, incorporating
many or all reported for any of the genetic cardiomyopathies
(DCM, HCM, restrictive cardiomyopathy, ARVD/C, and
left ventricular noncompaction), are rapidly emerging using
NGS methods. Although this increase in data comes with a
host of limitations and complications in interpretation,
FDC testing sensitivity (the probability of finding a genetic
cause with the genetic testing) now ranges from 15% to
25%, making pre-symptomatic testing feasible. Testing
laboratories for DCM genes are catalogued at GeneTests
(102), an online service hosted by the National Center for
Biotechnology Information.
The Genetic Information Nondiscrimination Act of 2008.
After many years of effort, a new federal law called the
Genetic Information Nondiscrimination Act now protects
individuals from genetic discrimination in health care or
employment. Further information is available at the Na-
tional Genome Research Institute website (103).
Ongoing Issues
Clinical progress. Despite the evidence supporting a ge-
netic basis of IDC/FDC, the implementation of guidelines
(13) by practitioners has been tepid. Adherence to such
guidelines will require a shift in focus from strictly thera-
peutic measures for a single patient presenting with ad-
vanced disease to the consideration and assessment of DCM
risk for an entire family (Fig. 1) (1,13,16).
The rationale for these recommendations is that most
IDC/DCM presents late in its causal pathway (advanced
disease, usually with heart failure or sudden cardiac death),
but early detection of asymptomatic DCM through screen-
ing enables presymptomatic intervention that may prevent
or ameliorate the progression to advanced disease (95).
With a new IDC diagnosis, genetic risk evaluation should
be initiated, including taking a 3- to 4-generation family
history and recommending that first-degree family members
undergo clinical cardiovascular screening (Fig. 1). Clinical
genetic testing may also be warranted, including the com-
petent interpretation of genetic results with appropriate
counseling (1,16). All of this may require referral of patients
to centers providing expertise in cardiovascular genetics and
guidance on implementation of gene- and/or mutation-
specific therapies if indicated (13), ideally in centers with
geneticists or genetic counselors working in collaboration
with cardiologists (95).
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though rare variants have been identified for more than
30 genes, we estimate that this accounts for only one-
third of genetic causes of FDC. We predict that this
Figure 1 Flow Diagram of Genetic Risk Assessment for Patient
The boxes on the left and right provide guidance for negative or positive results, r
boxes. *Always search for history or examination findings consistent with syndrom
syndromic disease in the proband or family members, strongly consider referral to
Some features of early onset conduction system disease or arrhythmia (usually fro
variants of unknown significance are not helpful for predictive testing. DCM  dila
FH  family history; IDC  idiopathic dilated cardiomyopathy.number will expand significantly. Discovery of additionalgenetic causes of DCM is still key to further understanding
DCM genetics.
Genetic model for DCM. We have only scratched the
surface in understanding DCM genetics. We have almost
wly Diagnosed With IDC or FDC
ively, based on the results of history or testing recommended in the central
ase, particularly skeletal muscle symptoms. However, with any suggestion of
eticist or cardiovascular (CV) genetic medicine clinic with genetics collaboration.
in A/C rare variants) may be particularly susceptible to genetic testing. Rare
rdiomyopathy; ECG  electrocardiogram; FDC  familial dilated cardiomyopathy;s Ne
espect
ic dise
a gen
m lam
ted cano insight into the causes of the marked variation in age of
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for the same mutation within a large extended family or
between families with the same variant. Gene-environment
interactions may explain some of the variability, but addi-
tional genetic variation may also explain a portion. Most of
the FDC genetic data thus far support a 1-gene Mendelian
model with marked locus (many genes) and marked allelic
heterogeneity (many private mutations within any one
gene). The impact of multiple mutations in the same
individual has been recognized for HCM (104–109) and
LQTS (108,110), for which 2 or more mutations have been
shown to be associated with earlier onset and more severe
disease in 3% to 7% of patients. However, considerable
additional genetic variation may be at play. Such genetic
variation could include “less common” common variants
(e.g., allele frequencies of 0.5% to 5%), additional rare
variants (including the biallelic models as shown in HCM
and ARVD/C [111,112]), epigenetic factors, gene promoter
site variants, or alterations in other genetically driven
regulatory processes such as microRNAs or their target
sites. All of these potential variations remain to be evaluated
for genetic DCM.
Is IDC a genetic disease? A related issue involves the
genetics of IDC, or DCM after all known causes (except
genetic) have been ruled out, and its relationship to FDC.
This issue is important because understanding the genetic
basis of IDC could have a major public health impact, as
nonischemic DCM makes up a significant proportion of all
forms of cardiomyopathy and IDC is by far the largest
component of nonischemic DCM. Here we differentiate
“true” IDC as a patient with IDC who has had their
first-degree family members clinically screened (history,
examination, echocardiogram, electrocardiogram) to rule
out FDC versus a “presumptive” IDC—one who is negative
for familial disease by a careful 3- to 4-generation family
history but has not had family members screened beyond
the FH. Preliminary data from our resequencing studies
have suggested that the frequency of possibly or likely
disease-causing rare variants in a cohort of FDC and IDC
probands (300 in total) was similar (35,39). However, in
those studies, the family members of the IDC probands
were not systematically screened beyond FH, making it
difficult to accurately assess the familial nature of disease in
the “apparently sporadic” IDC portion of our cohort.
Therefore, whether “true” sporadic IDC differs from FDC
in gene composition, penetrance, or expressivity remains
untested in a large prospective study.
Summary
Recent progress for DCM genetics has been significant,
although much remains to be learned. Clinical genetic
testing is rapidly emerging, and NGS technology now
permits patients to undergo clinical genetic testing for many
genes at reduced cost. However, enthusiasm for DCM
genetic testing remains tempered in 2011 in large partbecause of the testing sensitivity of 15% to 25% and the
plethora of DCM genes that make the rare variants “estab-
lished as disease causing” in any one gene only a very few.
The discovery of new DCM genes and other DCM genetic
causes, accelerated now by exome sequencing and soon by
WGS, will lead to knowledge of the remainder of the
genetic makeup of FDC and IDC. The careful and system-
atic phenotyping of DCM (whether sporadic or familial)
probands and family members, when combined with the
cataloging of many DCM rare variants, will enable DCM
genetics to move into the mainstream of cardiovascular
genetic medicine.
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